FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.

Article  PubMed  Google Scholar 

Evans J, Chapple A, Salisbury H, Corrie P, Ziebland S. “It can’t be very important because it comes and goes”–patients’ accounts of intermittent symptoms preceding a pancreatic cancer diagnosis: a qualitative study. BMJ Open. 2014;4(2): e004215. https://doi.org/10.1136/bmjopen-2013-004215.

Article  PubMed  PubMed Central  Google Scholar 

Adamska A, Elaskalani O, Emmanouilidi A, Kim M, Abdol Razak NB, Metharom P, et al. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv Biol Regul. 2018;68:77–87. https://doi.org/10.1016/j.jbior.2017.11.007.

CAS  Article  PubMed  Google Scholar 

Murakami T, Hiroshima Y, Matsuyama R, Homma Y, Hoffman RM, Endo I. Role of the tumor microenvironment in pancreatic cancer. Ann Gastroenterol Surg. 2019;3(2):130–7. https://doi.org/10.1002/ags3.12225.

Article  PubMed  PubMed Central  Google Scholar 

Andrén-Sandberg A. Pancreatic cancer: chemotherapy and radiotherapy. N Am J Med Sci. 2011;3(1):1–12. https://doi.org/10.4297/najms.2011.31.

Article  PubMed  PubMed Central  Google Scholar 

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. https://doi.org/10.1056/NEJMoa1011923.

CAS  Article  PubMed  Google Scholar 

Vreeland TJ, McAllister F, Javadi S, Prakash LR, Fogelman DR, Ho L, et al. Benefit of gemcitabine/nab-paclitaxel rescue of patients with borderline resectable or locally advanced pancreatic adenocarcinoma after early failure of FOLFIRINOX. Pancreas. 2019;48(6):837–43. https://doi.org/10.1097/MPA.0000000000001345.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Cavanna L, Stroppa EM, Citterio C, Mordenti P, Di Nunzio C, Peveri S, et al. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience. Onco Targets Ther. 2019;12:3077–85. https://doi.org/10.2147/ott.s200754.

Yang F, Jin C, Fu DL, Warshaw AL. Modified FOLFIRINOX for resected pancreatic cancer: opportunities and challenges. World J Gastroenterol. 2019;25(23):2839–45. https://doi.org/10.3748/wjg.v25.i23.2839.

Article  PubMed  PubMed Central  Google Scholar 

Ueno H, Kosuge T. Adjuvant treatments for resectable pancreatic cancer. J Hepatobiliary Pancreat Surg. 2008;15(5):468–72. https://doi.org/10.1007/s00534-008-1357-3.

Article  PubMed  Google Scholar 

Abbassi R, Algül H. Palliative chemotherapy in pancreatic cancer-treatment sequences. Transl Gastroenterol Hepatol. 2019;4:56. https://doi.org/10.21037/tgh.2019.06.09.

Article  PubMed  PubMed Central  Google Scholar 

Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, et al. Gemcitabine/nab-paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis. Eur J Cancer. 2021;151:3–13. https://doi.org/10.1016/j.ejca.2021.03.040.

CAS  Article  PubMed  Google Scholar 

Niu J, Straubinger RM, Mager DE. Pharmacodynamic drug-drug interactions. Clin Pharmacol Ther. 2019;105(6):1395–406. https://doi.org/10.1002/cpt.1434.

Article  PubMed  Google Scholar 

Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3(3): e00149. https://doi.org/10.1002/prp2.149.

Article  PubMed  PubMed Central  Google Scholar 

Molins EAG, Jusko WJ. Assessment of three-drug combination pharmacodynamic interactions in pancreatic cancer cells. Aaps j. 2018;20(5):80. https://doi.org/10.1208/s12248-018-0235-4.

CAS  Article  PubMed  Google Scholar 

Mager DE, Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2008;83(6):909–12. https://doi.org/10.1038/clpt.2008.52.

CAS  Article  PubMed  Google Scholar 

Zimmer A, Katzir I, Dekel E, Mayo AE, Alon U. Prediction of multidimensional drug dose responses based on measurements of drug pairs. Proc Natl Acad Sci U S A. 2016;113(37):10442–7. https://doi.org/10.1073/pnas.1606301113.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Nelson SR, Zhang C, Roche S, O’Neill F, Swan N, Luo Y, et al. Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development. Sci Rep. 2020;10(1):2778. https://doi.org/10.1038/s41598-020-59368-7.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Hou S, Tiriac H, Sridharan BP, Scampavia L, Madoux F, Seldin J, et al. Advanced development of primary pancreatic organoid tumor models for high-throughput phenotypic drug screening. SLAS Discov. 2018;23(6):574–84. https://doi.org/10.1177/2472555218766842.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Ande A, Vaidya TR, Tran BN, Vicchiarelli M, Brown AN, Ait-Oudhia S. Utility of a Novel three-dimensional and dynamic (3DD) cell culture system for PK/PD studies: evaluation of a triple combination therapy at overcoming anti-HER2 Treatment resistance in breast cancer. Front Pharmacol. 2018;9:403. https://doi.org/10.3389/fphar.2018.00403.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Roche S, O’Neill F, Murphy J, Swan N, Meiller J, Conlon NT, et al. Establishment and characterisation by expression microarray of patient-derived xenograft panel of human pancreatic adenocarcinoma patients. Int J Mol Sci. 2020;21(3).  https://doi.org/10.3390/ijms21030962.

Martin A, Clynes M. Comparison of 5 microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays. Cytotechnology. 1993;11(1):49–58. https://doi.org/10.1007/bf00749057.

CAS  Article  PubMed  Google Scholar 

Y. Di Veroli G, Fornari C, Wang D, Mollard Sv, Bramhall JL, M. Richards F, et al. Combenefit: an interactive platform for the analysis and visualisation of drug combinations. Bioinformatics. 2016;32 2866–8.

Bliss CI. The toxicity of poisons applied jointly. Annals of Applied Biology1939. p. 585–615.

Webb JL. Effect of more than one inhibitor. Enzyme and Metabolic Inhibitors1963. p. 66–79.

Bruckner HW, Spigelman M. Leucovorin as a clinical potentiator of 5-fluorouracil toxicity and anticancer efficacy. Mt Sinai J Med. 1988;55(5):390–4.

CAS  PubMed  Google Scholar 

Showalter SL, Showalter TN, Witkiewicz A, Havens R, Kennedy EP, Hucl T, et al. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther. 2008;7(7):986–94. https://doi.org/10.4161/cbt.7.7.6181.

Harrison RL. Introduction to Monte Carlo simulation. AIP Conf Proc. 2010;1204:17–21. https://doi.org/10.1063/1.3295638.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Chowbay B XJ, Wong JXG, Marvalim C, Ng SL, Sutiman N, Leong WF. Effects of oxaliplatin, capecitabine and irinotecan (OXIRI) on PDAC cell lines carrying different Kras mutational status ASCO annual meeting: Journal of Clinical Oncology; 2016.

Kim Y, Han D, Min H, Jin J, Yi EC. Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines. Mol Cells. 2014;37(12):888–98. https://doi.org/10.14348/molcells.2014.0207.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Peters GJ, van Groeningen CJ, van der Wilt CL, Meijer S, Smid K, Laurensse E, et al. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin. Semin Oncol. 1992;19(2 Suppl 3):26–35.

CAS  PubMed  Google Scholar 

Van der Wilt CL, Pinedo HM, Smid K, Peters GJ. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res. 1992;52(18):4922–8.

PubMed  Google Scholar 

Tsujimoto H, Tsukioka S, Ono S, Sakamoto E, Sakamoto K, Tsuta K, et al. Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase. Oncol Lett. 2010;1(6):973–80. https://doi.org/10.3892/ol.2010.172.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Sakamoto E, Tsukioka S, Oie S, Kobunai T, Tsujimoto H, Sakamoto K, et al. Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem Biophys Res Commun. 2008;365(4):801–7. https://doi.org/10.1016/j.bbrc.2007.11.043.

CAS  Article  PubMed  Google Scholar 

Nakamura A, Nakajima G, Okuyama R, Kuramochi H, Kondoh Y, Kanemura T, et al. Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase. Gastric Cancer. 2014;17(1):188–95. https://doi.org/10.1007/s10120-013-0249-7.

CAS  Article  PubMed  Google Scholar 

Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res. 1999;5(5):1189–96.

CAS  PubMed  Google Scholar 

Lei F, Xi X, Rachagani S, Seshacharyulu P, Talmon GA, Ponnusamy MP, et al. Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer. J Control Release. 2021;330:1229–43. https://doi.org/10.1016/j.jconrel.2020.11.029.

CAS  Article  PubMed  Google Scholar 

Deer EL, González-Hernández J, Coursen JD, Shea JE, Ngatia J, Scaife CL, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39(4):425–35. https://doi.org/10.1097/MPA.0b013e3181c15963.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Yao J, Cai HH, Wei JS, An Y, Ji ZL, Lu ZP, et al. Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells. Oncol Rep. 2010;23(5):1375–82. https://doi.org/10.3892/or_00000774.

CAS  Article  PubMed  Google Scholar 

Rao CV, Mohammed A. New insights into pancreatic cancer stem cells. World J Stem Cells. 2015;7(3):547–55. https://doi.org/10.4252/wjsc.v7.i3.547.

Article  PubMed  PubMed Central  Google Scholar 

Qin B, Tanaka R, Shibata Y, Arita S, Ariyama H, Kusaba H, et al. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines. Anticancer Drugs. 2006;17(4):445–53. https://doi.org/10.1097/01.cad.0000198912.98442.cd.

留言 (0)

沒有登入
gif